LOS ANGELES– BiologyWorks™, a medical test developer with a mission to deliver fast, affordable, and accurate molecular testing, today announced the appointment of Hunt Ramsbottom to CEO. Ramsbottom’s appointment comes as the company prepares to launch its molecular testing solution to commercial market this year.
The BiologyWorks k(now)™ handheld device uses cutting-edge software and hardware to deliver PCR-level results in minutes for COVID-19, Influenza A/B, Hepatitis B, Streptococcus, STDs, AIDS/HIV, Pneumonia and much more.
“Hunt brings significant expertise in managing and building companies in highly regulated industries that require manufacturing and large-scale distribution systems and relationships,” said Peter Marx, co-founder of BiologyWorks. “We are fortunate to have his guiding hand and sharp insight as we navigate the launch of our revolutionary new testing product.”
Ramsbottom previously served as CEO for six public and private companies and brings more than 25 years of experience leading technology and manufacturing firms. He has raised over $2.5 billion and led acquisitions of over 70 companies while driving organic growth.
“BiologyWorks is rich with intellectual capital from its impressive team of scientists, virologists, biologists, technologists, and creatives. The power of this team, combined with the company’s patents from the Alfred Mann Foundation and support from the Bill and Melinda Gates Foundation, have propelled the company into next-gen molecular testing,” noted Ramsbottom. “I’m honored to have the opportunity to further build on this groundbreaking work that is changing the face of the healthcare industry.”
Using technologies only recently available, BiologyWorks developed a handheld molecular test that is fast, affordable, reusable, and digital. The device delivers highly accurate results about any infection or disease with a recognizable gene sequence, starting with COVID-19.
